FierceBiotech1h
NIH caps 'indirect costs' in biomedical research grants, aims to save $4B per year
With a yearly budget of nearly $48 billion, the NIH is the world’s largest public funder of biomedical research. The agency's ...
FierceBiotech1h
FDA amplifies BD atherectomy safety alert following 4 deaths
The FDA is getting the word out on a high-risk issue related to artery-clearing catheters from BD’s Bard Peripheral Vascular ...
FierceBiotech2h
Globus Medical to buy neurostim developer Nevro for $250M
Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...
FierceBiotech2h
Boehringer widens fibrosis drug’s approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...
FierceBiotech3h
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
FierceBiotech5h
Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger
Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...
FierceBiotech8h
Pliant pauses phase 2 lung fibrosis trial on advice of safety committee
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...